Boston Trust Walden Corp lowered its stake in CorVel Corp. (NASDAQ:CRVL - Free Report) by 1.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 677,830 shares of the business services provider's stock after selling 12,223 shares during the quarter. Boston Trust Walden Corp owned about 1.32% of CorVel worth $75,897,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the stock. Mayfair Advisory Group LLC lifted its stake in shares of CorVel by 7.2% in the 1st quarter. Mayfair Advisory Group LLC now owns 2,212 shares of the business services provider's stock valued at $248,000 after purchasing an additional 148 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of CorVel by 3.3% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 14,345 shares of the business services provider's stock valued at $1,606,000 after purchasing an additional 461 shares during the period. Assenagon Asset Management S.A. acquired a new position in shares of CorVel in the 1st quarter valued at $1,398,000. SG Americas Securities LLC lifted its stake in shares of CorVel by 519.5% in the 1st quarter. SG Americas Securities LLC now owns 9,416 shares of the business services provider's stock valued at $1,054,000 after purchasing an additional 7,896 shares during the period. Finally, GAMMA Investing LLC lifted its stake in shares of CorVel by 58.6% in the 1st quarter. GAMMA Investing LLC now owns 685 shares of the business services provider's stock valued at $77,000 after purchasing an additional 253 shares during the period. Institutional investors and hedge funds own 51.36% of the company's stock.
Analysts Set New Price Targets
Separately, Wall Street Zen raised CorVel from a "hold" rating to a "buy" rating in a research note on Friday, April 18th.
Read Our Latest Stock Analysis on CorVel
CorVel Trading Down 0.2%
Shares of CorVel stock opened at $102.50 on Thursday. The company has a market capitalization of $5.26 billion, a PE ratio of 55.81 and a beta of 1.02. CorVel Corp. has a 12 month low of $81.46 and a 12 month high of $128.61. The stock's fifty day simple moving average is $111.18 and its 200 day simple moving average is $115.37.
CorVel (NASDAQ:CRVL - Get Free Report) last issued its quarterly earnings data on Thursday, May 22nd. The business services provider reported $0.51 EPS for the quarter. The business had revenue of $231.51 million for the quarter. CorVel had a return on equity of 32.55% and a net margin of 10.63%.
Insider Buying and Selling
In related news, Director R Judd Jessup sold 687 shares of the firm's stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $111.25, for a total transaction of $76,428.75. Following the sale, the director now owns 128,832 shares of the company's stock, valued at approximately $14,332,560. This trade represents a 0.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Maxim Shishin sold 2,400 shares of the firm's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $108.09, for a total value of $259,416.00. Following the sale, the insider now directly owns 7,050 shares in the company, valued at $762,034.50. The trade was a 25.40% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,602 shares of company stock valued at $3,379,049. 47.57% of the stock is owned by company insiders.
CorVel Profile
(
Free Report)
CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.
Further Reading
Want to see what other hedge funds are holding CRVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CorVel Corp. (NASDAQ:CRVL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CorVel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorVel wasn't on the list.
While CorVel currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
